Recent News

• 09.25.2026 - Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
• 09.24.2026 - Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
• 09.23.2026 - Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
• 09.23.2026 - Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
• 09.18.2026 - Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
• 09.11.2026 - Glucotrack Announces $11.5 Million Financing
• 09.08.2026 - Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions
• 09.02.2026 - Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business
• 08.27.2026 - Glucotrack, Inc. Announces Reverse Stock Split
• 08.25.2026 - Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100

Recent Filings

• 09.24.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.24.2026 - 8-K Current report
• 09.24.2026 - EX-99.1 EX-99.1
• 09.23.2026 - 425 Prospectuses and communications, business combinations
• 09.23.2026 - 8-K Current report
• 09.23.2026 - EX-99.1 EX-99.1
• 09.18.2026 - 8-K Current report
• 09.18.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 09.14.2026 - 8-K Current report
• 09.11.2026 - 8-K Current report